Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors
Stock Information for Syros Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.